A combination regimen by lopinave/litonawe, emtricitabine and tenofovir alafenamide fumarate for treatment of novel coronavirus pneumonia (TARCoV)
10.3760/cma.j.issn.1671-0282.2020.03.009
- VernacularTitle:洛匹那韦/利托那韦联合恩曲他滨/丙酚替诺福韦方案用于新型冠状病毒肺炎治疗的临床研究方案（TARCoV研究）
- Author:
Hua JIANG
1
;
Yu WANG
;
Kai WANG
;
Xingxiang YANG
;
Jiancheng ZHANG
;
Hongfei DENG
;
Lu WANG
;
Jun ZENG
Author Information
1. 电子科技大学附属医院·四川省人民医院 急诊医学与灾难医学研究所，成都 610072
- From:
Chinese Journal of Emergency Medicine
2020;29(3):346-349
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the efficacy of a combination regimen by Lopinave/Litonawe (LPV/r), emtricitabine and tenofovir alafenamide fumarate (FTC/TAF) for the treatment of novel coronavirus pneumonia.Methods:We design the protocol as a real world study, which includes two groups: prospective intervention cohort (T1) and historical control group (T2). For the T1 group, ninety patients who are diagnosed as NCP will be enrolled. All patients in the T1 group will receive standard therapies following the recommendation in the Guidelines of National Commission of Health, and will be administered an anti-virus regimen including LPV/r and FTC/TAF. The T2 group will enroll patients who have received single regimen of LPV/r. The major outcome is the survival rate of patients. Secondary outcomes are the time of seroconversion of RNA, ARDS progression rate and length of hospital stay.Conclusions:The results of this real world study might provide clinical practitioners a high efficiency and fast antivirus regimen for novel coronavirus pneumonia patients. In addition, the conduction of this study will accelerate screening for other new effective therapeutic method.
